Real-World Evidence Demonstrates Diminished Outcomes for Adult Patients with RRMM After 1-3 Prior LoT1

Survival outcomes by number of prior LoT

Image showing survival probability at 6 months median rwPFS8 (95% CI; 5.5-6.7)

6 MONTHS MEDIAN rwPFS*(95% CI; 5.5-6.7)

STUDY DESIGN

CI=confidence interval; LoT=line(s) of therapy; mo=months; PL=prior line; RRMM=relapsed or refractory multiple myeloma;

rwPFS=real-world progression-free survival; TTNT=time to next treatment.

*rwPFS was defined as any event of disease progression, change in anti-myeloma treatment, or death.

GET IN
TOUCH

Learn More About CARVYKTI®

GET IN TOUCH

SCROLL TO TOP ↑

Reference

  1. Dhakal B et al. Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database. Poster presented at The 19th International Myeloma Society (IMS) Annual Meeting; August 25-27, 2022; Los Angeles, CA.